{
  "docId": "019de076-9336-7344-93bc-154185328b25",
  "docSlug": "edea36d6b00ed662cafb2da1a03c41ae",
  "documentTitle": "BenevolentAI | Investor Conference Presentation Deck | 22 slides",
  "authorId": "benevolentai",
  "authorName": "BenevolentAI",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-01-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 9,
  "pageCount": 22,
  "prevPage": 8,
  "nextPage": 10,
  "slideType": "key_takeaways",
  "function": "summarize",
  "density": "overcrowded",
  "nDataPoints": 0,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-9336-7344-93bc-154185328b25/9",
  "deckHref": "/decks/019de076-9336-7344-93bc-154185328b25",
  "deckJsonHref": "/decks/019de076-9336-7344-93bc-154185328b25.json",
  "deckAnchorHref": "/decks/019de076-9336-7344-93bc-154185328b25#slide-9",
  "components": [
    {
      "bbox": {
        "h": 0.05,
        "w": 0.1,
        "x": 0.8,
        "y": 0.22
      },
      "kind": "image",
      "text": "AstraZeneca logo",
      "attrs": null,
      "subkind": "logo",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "090d299c-1549-4eb9-a37a-21d8dd715529",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.1,
        "x": 0.8,
        "y": 0.59
      },
      "kind": "image",
      "text": "Lilly and FDA logos",
      "attrs": null,
      "subkind": "logo",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "398a7e93-9b7a-42bd-b7fa-60b7bdb443dd",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.1,
        "x": 0.8,
        "y": 0.41
      },
      "kind": "image",
      "text": "Merck logo",
      "attrs": null,
      "subkind": "logo",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "af2c385d-9ed3-40bb-aacb-d86763548b27",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.7,
        "x": 0.05,
        "y": 0.76
      },
      "kind": "list",
      "text": "Internal Pipeline of Novel, Best in Class And First in Class Programmes: Demonstrates utility to find novel insights; Develop and advance unique and differentiated molecules",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6287b09d-891c-44e8-b3bc-08912a599964",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.7,
        "x": 0.05,
        "y": 0.2
      },
      "kind": "list",
      "text": "Target Identification with Big Pharma: Collaboration with AZ expanded from two to four disease areas; Delivered multiple novel targets into AZ's pipeline",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8eb2d244-4731-4e41-868c-ed3a953a9c4b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.7,
        "x": 0.05,
        "y": 0.38
      },
      "kind": "list",
      "text": "Hit Identification through to Preclinical Stage with Big Pharma: Collaboration with Merck in three therapeutic areas; Validation of our chemistry tech and lab capabilities",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "acae8f37-4a61-4171-b928-4c24639b5b6f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.18,
        "w": 0.7,
        "x": 0.05,
        "y": 0.55
      },
      "kind": "list",
      "text": "Proven Novel Indication Expansion Leading to FDA Approval - Fast: Identified baricitinib as a potential COVID-19 treatment; Led to FDA emergency use approval in Nov 2020 and full approval in May 2022",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ea116469-7411-4a90-8851-366f0b6ea08e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.6,
        "x": 0.05,
        "y": 0.06
      },
      "kind": "title",
      "text": "Validation of the Benevolent Platform™",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "98e6e302-8ecd-433e-a90c-df17756cf663",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Evidence Matrix",
      "slug": "evidence-matrix",
      "agent": "Designer",
      "layer": "slide",
      "matchId": "25fefbed-848c-4cb4-af12-1f4147a6aebb",
      "evidence": "list/bullet: Proven Novel Indication Expansion Leading to FDA Approval - Fast: Identified baricitinib as a potential COVID-19 treatment; Led to FDA emergency use approval in Nov 2020 and full approval in May 2022",
      "confidence": 0.7
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [
    {
      "to": 9,
      "from": 3,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "0a7dc950-f012-4806-a974-ccc12cfbaec1",
      "evidence": "The presentation emphasizes the potential of the Benevolent Platform™.",
      "position": 0,
      "objective": "Highlighting the importance of AI-driven drug discovery",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}